109032-22-6

Basic information

• Product Name: 4-HYDROXY NIMESULIDE
• Synonyms: 4-HYDROXY NIMESULIDE;N-[2-(4-Hydroxyphenoxy)-4-nitrophenyl]-methanesulfonamide;4-nitro-2-(4'-hydroxyphenoxy)methanesulfonanilide;4-[2-(Mesylamino)-5-nitrophenoxy]phenol;N-[4-Nitro-2-(4-hydroxyphenoxy)phenyl]methanesulfonamide
• CAS NO: 109032-22-6
• Molecular Formula: C₁₃H₁₂N₂O₆S
• Molecular Weight: 324.31
• Product Categories: Intermediates & Fine Chemicals;Metabolites & Impurities;Pharmaceuticals;Aromatics;Sulfur & Selenium Compounds
• Mol File: 109032-22-6.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 496.7°Cat760mmHg
• Flash Point: 254.2°C
• Appearance: /
• Density: 1.538g/cm³
• Vapor Pressure: 1.72E-10mmHg at 25°C
• Refractive Index: 1.66
• PKA: 6.16±0.10(Predicted)
• CAS DataBase Reference: 4-HYDROXY NIMESULIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-HYDROXY NIMESULIDE(109032-22-6)
• EPA Substance Registry System: 4-HYDROXY NIMESULIDE(109032-22-6)

Safety Data

• Hazardous Substances Data: 109032-22-6(Hazardous Substances Data)

Usage

Description

4-Hydroxy Nimesulide, also known as a main metabolite of Nimesulide (N477500), is a chemical compound derived from the parent drug Nimesulide. It possesses specific chemical properties that make it a significant entity in pharmaceutical research and development.
Used in Pharmaceutical Industry:
4-Hydroxy Nimesulide is used as an active metabolite for enhancing the therapeutic effects of Nimesulide. It contributes to the anti-inflammatory, analgesic, and antipyretic properties of the parent drug, thereby improving patient outcomes in the treatment of various conditions such as pain, fever, and inflammation.
Used in Research and Development:
In the field of pharmaceutical research and development, 4-Hydroxy Nimesulide is utilized as a subject of study to understand its pharmacological properties, potential side effects, and interactions with other drugs or compounds. This research aids in the optimization of Nimesulide-based treatments and the development of new drugs with improved safety and efficacy profiles.

InChI:InChI=1/C13H12N2O6S/c1-22(19,20)14-12-7-2-9(15(17)18)8-13(12)21-11-5-3-10(16)4-6-11/h2-8,14,16H,1H3

Upstream product

• 88-73-3 2-Chloronitrobenzene 
• 150-76-5 4-methoxy-phenol 
• 105901-39-1 2-(4-Methoxyphenoxy)benzenamine 
• 58656-16-9 2-(4-methoxyphenoxy)nitrobenzene 
• 721448-65-3 N-(2-(4-methoxyphenoxy)phenyl)methanesulfonamide 
• 51765-76-5 N-(2-(4-methoxyphenoxy)-4-nitrophenyl)methanesulfonamide 
• 51803-78-2 nimesulide 

Relevant articles and documents

Radiosynthesis and in Vivo and ex Vivo Evaluation of Isomeric [11C]-methoxy Analogs of Nimesulide as Brain Cyclooxygenase-2-Targeted Imaging Agents

Our previous studies identified that nimesulide analogs which bear a methoxy substituent at the paraposition of the phenyl ring could be potential radiotracer candidates for detecting disorders related to cyclooxygenase-2 (COX-2) expression and activity in vivo using positron emission tomography (PET) in the brain. The present study was conducted to evaluate the in vivo characteristics of 11C-labeled para-methoxy nimesulide ([11C]1d) as a brain COX-2-targeted imaging agent compared to other isomeric methoxy analogs of nimesulide ([11C]1b and [11C]1c). [11C]1b–d were synthesized with reasonable yield and purity by the methylation of the O-desmethyl precursor with [11C]methyl triflate in the presence of NaOH at room temperature. We performed in vivo biodistribution analysis, brain PET imaging, ex vivo autoradiography, and metabolite analysis in mice. The uptake of [11C]1b–d was lower in the brain than in other tissues, including in the blood, and both [11C]1c and [11C]1d were rapidly metabolized. However, [11C]1d showed a small, but significant, specific signal and heterogeneous distribution in the brain. In vivo evaluation suggested that [11C]1d might correlate with COX-2 expression in the brain. Given its instability in vivo, [11C]1d seems unsuitable as a brain-COX-2 radioimaging agent. Further structural refinement of these radiotracers is necessary to enhance their uptake in the brain and to achieve sufficient metabolic stability.

Biomimetic reduction of nimesulide with NaBH4 catalyzed by metalloporphyrins.

The biomimetic reduction of anti-inflammatory drug, nimesulide (1) with sodium borohydride catalyzed by 5,10,15,20-tetraarylporphyrinatoiron(III) chlorides [TAPFe(III)Cl] has been studied in organic solvents under anaerobic and aerobic conditions.